Assessing lead time of selected ovarian cancer biomarkers: A nested case-control study

Journal of the National Cancer Institute

Volumn 102, Issue 1, 2010, Pages 26-38

  Anderson, Garnet L ^a   McIntosh, Martin ^a   Wu, Lieling ^a   Barnett, Matt ^a   Goodman, Gary ^a   Thorpe, Jason D ^a   Bergan, Lindsay ^a   Thornquist, Mark D ^a   Scholler, Nathalie ^b   Kim, Nam ^c   O'Briant, Kathy ^a   Drescher, Charles ^a   Urban, Nicole ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DiaDeXus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CELL PROTEIN; DECOY RECEPTOR 3; HUMAN EPIDIDYMIS PROTEIN 4; MESOTHELIN; PROTEIN B7 H4; PROTEIN SPONDIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD80; AREA UNDER CURVE; CA-125 ANTIGEN; CASE-CONTROL STUDIES; EPIDIDYMAL SECRETORY PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOASSAY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 74049084937     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp438     Document Type: Article

References (62)

1. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer. 2003; 3 ( 4 ): 243-252.
2. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004; 3 ( 4 ): 355-366.
3. Bast RC, Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002; 107: 61-97.
4. Bast RC. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc. 2004; 155: 233-248.
5. Zurawski VR, Orjaseter H, Anderson A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance to early detection of ovarian cancer. Int J Cancer. 1988; 42 ( 5 ): 667-680.
6. Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992; 80 ( 1 ): 14-18.
7. Woolas RP, Xu F, Jacobs IJ, et al. Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. Int J Gynecol Cancer. 1996; 6 ( 2 ): 156-158.
8. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in post-menopausal women. J Clin Oncol. 2003; 21 ( suppl 10 ): 206S-210S.
9. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93 ( 14 ): 1054-1061.
10. Thornquist MD, Omenn GS, Goodman GE, et al. Statistical design and monitoring of the Carotene and Retinol Effi cacy Trial (CARET). Control Clin Trials. 1993; 14 ( 4 ): 308-324.
11. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics. 2002; 58 ( 3 ): 657-664.
12. McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003; 4 ( 1 ): 27-40.
13. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at fi rst relapse of disease. Eur J Cancer. 1994; 30A ( 14 ): 2082-2084.
14. Norum LF, Erikstein B, Nustad K. Elevated CA125 in breast cancer-a sign of advanced disease. Tumour Biol. 2001; 22 ( 4 ): 223-228.
15. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypep-tide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003; 23 ( 18 ): 531-536.
16. Bairey O, Blickstein D, Stark P, et al. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003; 44 ( 10 ): 1733-1738.
17. Burney IA, Siddiqui T, Siddiqui I. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 1999; 85 ( 3 ): 755-756.
18. Kutluk T, Varan A, Erbas B, Buyukpamukcu M. Serum CA 125 levels in children with non-Hodgkin's lymphoma. Pediatr Hematol Oncol. 1999; 16 ( 4 ): 311-319.
19. Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist. 2004; 9 ( 4 ): 417-421.
20. Camera A, Villa MR, Rocco S, et al. Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement. Cancer. 2000; 88 ( 1 ): 75-78.
21. Yamamoto M, Baba H, Toh Y, Okamura T, Maehara Y. Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol. 2007; 33 ( 7 ): 471-476.
22. Whiteley MS, Marshall J. Raised serum CA125 level in leiomyoma and leiomyosarcoma of gastrointestinal origin. Br J Surg. 1993; 80 ( 12 ): 1551.
23. Kui Wong N, Easton RL, Panico M, et al. Characterization of the oligo-saccharides associated with the human ovarian tumor marker CA125. J Biol Chem. 2003; 278 ( 31 ): 28619-28634.
24. Belisle JA, Gubbels JA, Raphael CA, et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology. 2007; 122 ( 3 ): 418-429.
25. Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007; 1: 513-523.
26. Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25 ( 24 ): 3615-3620.
27. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005; 15 ( 5 ): 679-691.
28. Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identifi ed from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64 ( 16 ): 5882-5890.
29. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profi ling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17 ( 10 ): 2872-2881.
30. Palmer C, Duan X, Hawley S, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE. 2008; 3 ( 7 ): e2633.
31. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63 ( 13 ): 3695-3700.
32. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65 ( 6 ): 2162-2169.
33. Galgano M, Hampton G, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19 ( 6 ): 847-853.
34. Scholler N, Crawford M, Sato A, et al. Bead-based ELISA assays for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006; 12 ( 7, pt 1 ): 2117-2124.
35. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93 ( 1 ): 136-140.
36. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004; 279 ( 10 ): 9190-9198.
37. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affi nity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5 ( 1 ): 50.
38. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry. 2008; 47 ( 27 ): 6991-7000.
39. Zacks MA, Garg N. Recent developments in the molecular, biochemical and functional characterization of GPI8 and the GPI-anchoring mechanism [review]. Mol Membr Biol. 2006; 23 ( 3 ): 209-225.
40. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000; 20 ( 8 ): 2902-2906.
41. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999; 96 ( 20 ): 11531-11536.
42. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004; 95 ( 1 ): 9-15.
43. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifi es a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006; 203 ( 4 ): 871-881.
44. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplifi cation of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998; 396 ( 6712 ): 699-703.
45. Simon I, Liu Y, Krall KL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007; 106 ( 1 ): 112-118.
46. Scholler N, Garvik B, Quarles T, Jiang S, Urban N. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods. 2006; 317 ( 1-2 ): 132-143.
47. Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/ Mesothelin-dependent cell attachment. Cancer Lett. 2007; 255 ( 2 ): 263-274.
48. Scholler N, Lowe K, Bergan L, et al. Use of yeast-secreted in vivo bioti-nylated recombinant antibodies (biobodies) in bead-based ELISA. Clin Cancer Res. 2008; 14 ( 9 ): 2647-2655.
49. Cleveland WS. Robust locally weighted regression and smoothing scat-terplots. J Am Stat Assoc. 1979; 74 ( 368 ): 829-836.
50. Pepe MS. The Statistical Evaluation of Medical Tests for Classifi cation and Prediction. Oxford Statistical Science Series. New York, NY: Oxford University Press; 2003.
51. Cox DR. Regression models and life-tables (with discussion). J Roy Stat Soc B. 1972; 34: 187-219.
52. McIntosh MW, Drescher C, Urban N, Hellstrom KE, Hellstrom I. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004; 95 ( 1 ): 9-15.
53. McIntosh MW, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev. 2002; 11 ( 2 ): 159-166.
54. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specifi city of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10 ( 4 ): 327-340.
55. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009; 113 ( 4 ): 775-782.
56. Bast RC, Siegal FP, Runowicz C, et al. Elevation of serum CA125 prior to diagnosis of epithelial ovarian carcinoma. Gynecol Oncol. 1985; 22 ( 1 ): 115-120.
57. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993; 269 ( 9 ): 1123-1126.
58. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001; 84 ( 5 ): 714-721.
59. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81 ( 24 ): 1879-1886.
60. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009; 27 ( 7 ): 633-641.
61. Faca V, Pitteri SJ, Newcomb L, et al. Contribution of protein fraction-ation to depth of analysis of the serum and plasma proteomes. J Proteome Res. 2007; 6 ( 9 ): 3558-3565.
62. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defi ning the target for early detection. PLoS Med. 2009; 6 ( 7): e1000114.